ChromaDex’s ingredient NIAGEN is sold directly to consumers as TRU NIAGEN, which is backed by clinical and scientific research establishing its safety and efficacy at elevating the coenzyme nicotinamide adenine dinucleotide (NAD) in humans. NAD is an important metabolite involved in virtually every metabolic process in the body, most notably energy metabolism and cell repair.
“Nestlé Health Science is a blue chip global company whose expertise in consumer health products is matched by their exceptional science,” said Rob Fried, CEO of ChromaDex. “We believe Nestlé Health Science’s portfolio with TRU NIAGEN will substantially advance their already strong market position. Importantly, this partnership will help educate people on the importance of elevating NAD levels with TRU NIAGEN. We are proud to be in business with Nestlé and look forward to a long, mutually beneficial relationship.”
Greg Behar, CEO of Nestlé Health Science, stated, “We are quite impressed with the science supporting TRU NIAGEN, and the excellent work done by the team of professionals at ChromaDex. We see this innovation as an important element of our product portfolio. We are confident that TRU NIAGEN combined with our Nestlé Health Science products and supported by strong scientific and clinical evidence will provide consumers the opportunity to improve the health of their cells with the power of nutrition.”
Under the terms of the agreement, NHSc will make an upfront payment of $4 million. CDXC will receive certain commercial milestone payments related to the sale of TRU NIAGEN to NHSc as well as tiered royalties.